The goal of the study is to examine multiple markers of anthropometrics, body
composition, sarcopenia and frailty and compare them to dual energy X-ray absorptiometry
(DXA) output, which is considered the current clinical gold-standard tool to measure body
composition. The result of this study will provide detailed data regarding the nutrition
and body composition within this Cystic Fibrosis population and also provide a baseline
evaluation for use of these biomarkers in the future studies including evaluation of
nutritional intervention. Further, the study will also include psychosocial and other
patient-reported outcomes and medical contributors to understand their contributions to
the nutritional failure in the adult advanced lung disease population. Finally, the study
will evaluate both established and emerging nutritional and body composition parameters
and link them to clinical outcomes in adults with CF across the spectrum of pulmonary
function.
Cohort 1: Participants are eligible if their percentage of predicated forced
expiratory volume in 1 second (ppFEV1) is <70% during the 12 months prior to
enrollment (>50% of measurements, eliminating periods of exacerbation)
- Cohort 2: Participants are eligible if their percentage of predicted forced
expiratory volume in 1 second (ppFEV1) is 70% or greater during the 12 months prior
to enrollment (>50% of measurements, eliminating periods of exacerbation).
- Both cohorts match by age, gender, race and CFTR genotype severity.
Exclusion Criteria
No prior solid organ transplantation
- No initiation of an investigation drug within 28 days prior to and including
Baseline Visit.
- No initiation of new chronic therapy (e.g., ibuprofen, azithromycin, inhaled
tobramycin, Cayston, CFTR modulator, etc.) within 28 days prior to and including
Baseline visit.
- No acute use of antibiotics (oral, inhaled or IV) or acute use of systemic
corticosteroids for respiratory tract symptoms within 14 days prior to and including
Baseline visit.
- For the BIA sub-study - Individuals with an implanted pacemaker will be excluded.
- No initiation of a drug for weight loss (such as a GLP-1 receptor agonist) or
bariatric surgery within 6-months prior to and including the Baseline visit.
- Patients with continued rapid change or extreme GI symptoms related to weight loss
therapy should be excluded at the discretion of the study investigator.
Study Design
Phase
Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective
Arm Groups
Arm
Description
Assigned Intervention
Cohort 1
Forced expiratory volume in 1 second (FEV1) <70% predicted during the 12 months prior to
enrollment (>50% of measurements, eliminating periods of exacerbation). If no stable
spirometry data are available in the 12 months prior to enrollment, from the prior 24
months will be used.
Diagnostic Test: BMI and lean mass index from DXA
Estimate and compare correlation between lean mass index from DXA and BMI
Diagnostic Test: Anthropometric Measurements
Skinfold will be assessed with calipers. Circumference will be measured with a tape
measure.
Diagnostic Test: Hand-grip strength
A small, handheld dynamometer will be used to measure grip strength, a measure of
function, on each hand.
Diagnostic Test: Six-minute walk Test
This will be another functional assessment of fitness. Participants will be asked to walk
at their normal pace for 6 minutes.The total distance walked in that time will be
measured.
Diagnostic Test: Sit-to-Stand Test
This will be used as a functional assessment of fitness and lower extremity strength.
Participants will start seated on a chair and be asked to complete as many sit-to-stand
repetitions without using their arms for one minute.
Diagnostic Test: Short physical performance battery (SPPB)
This is an assessment of frailty. The test is completed in approximately 8 minutes. The
test consists of 3 assessments: 1) Balance tests where the participant stands and tries
to balance with their feet in various positions for 10 seconds each without assistance
(side-by-side, heel-to-side, and heel-to-toe); 2) Two 4-meter gait speed tests; and 3)
Chair-stand tests (single chair stand, 5 chair stands).
Diagnostic Test: BIA Sub-study
A minimum of 50 individuals will be enrolled. Body composition will be assessed at each
study visit using study bioelectrical impendence analysis (BIA).
Diagnostic Test: Accelerometry to assess physical activity
Participants will be provided with a wrist-worn accelerometer/heart rate monitor at the
baseline study visit and asked to wear it continuously for at least 3-10 days (two
weekdays, one weekend day). Approximately every 3 months, the participant will be asked
to again wear the accelerometer. Participants will be able to keep their accelerometers.
Other: Gastrointestinal (GI) and nutrition questionnaires:
Subjects will complete surveys regarding gastrointestinal (GI) symptoms, including the
Patient Assessment of Constipation (PAC-SYM) Score, Patient Assessment of
Gastrointestinal Symptoms (PACGI-SYM) Score, the Bristol Stool Chart, and the scored
Patient-Generated Subjective Global Assessment (PG-SGA).
Other: Psychosocial questionnaire: PHQ-8
This is an 8-item scale that measures depressive symptoms over the past two weeks.
Other: Psychosocial questionnaire: GAD-7
This is a 7-items scale that measures anxiety symptoms over the past two weeks, from not
at all to nearly every day.
Other: Psychosocial questionnaire: The Treatment Self-Regulation Questionnaire (TSRQ)
This is a 15-item scale that assesses the degree to which participants' motivation is
autonomous or self-regulated.
Other: Psychosocial questionnaire: CF Fatalism Scale
The CF Fatalism Scale measures the belief in a lack of personal power or control over
one's future and has 13 items.
Other: Psychosocial questionnaire: Body Esteem Scale for Adolescents and Adults (BESAA)
The Body Esteem Scale for Adolescents and Adults (BESAA) is 23-item measurement of
self-evaluations of one's body or appearance.
Other: 12-month Questionnaire
A short questionnaire designed to explore participants' perspectives of the acceptability
and feasibility of nutritional assessments used in STRONG-CF will be given to all study
participants at the end of the study.
Other: Oral glucose tolerance testing (OGTT)
For subjects without previously diagnosed CFRD, an OGTT will be performed at baseline and
12-months with samples analyzed at the central lab.
Device: Continuous glucose monitoring (CGM)
Subjects will wear a Dexcom G6Pro sensor in blinded mode for three 10-day periods to
collect comprehensive glucose data.
Diagnostic Test: Chest CT scans (When available within the past 6 months in medical records)
Standard of Care chest CT images will be drawn from the medical record, as available,
from enrolled participants. FEV1 measurements prior to chest CT scans will be recorded to
account for possible illness occurring at the time of scanning. Quantitative assessment
of the pectoralis muscle area will be performed on the first single axial image above the
aortic arch. Any additional standard of care chest CT's that are performed while the
participant is enrolled in the study will also be collected and have a quantitative
assessment of the pectoralis muscle performed.
Diagnostic Test: Hologic Dual X-Ray Absorptiometry (DXA)
DXA measurements for whole body, total hip and lumbar spine will be acquired using the
Hologic DXA and standard positioning as noted in the DXA Manual of Operations. DXA will
be used to estimate total and regional body composition, which will include body fat and
lean body mass. This will be used as the gold standard from which to validate BIA and
MAMC.
Diagnostic Test: Ultrasound Sub-study of assessment of appendage muscles using ultrasound
A minimum of 50 individuals will be enrolled. At each study visit, participants will
undergo ultrasound muscle measurements (cross-sectional area and muscle thickness) of the
biceps and quadriceps on each (left and right) side of the body (4 total areas). These
measurements will be obtained in triplicate for each patient.
Diagnostic Test: Psychosocial questionnaire: Hunger Vital Sign questionnaire
Screening tool for identifying households at risk of food insecurity and poor health
outcomes linked to food insecurity with 3-items over the last 12 months.
Other: Respiratory symptom questionnaire: CRISS
Chronic Respiratory Infection Symptom Score (CRISS) is an 8-item respiratory symptom
questionnaire covering the last 24-hours.
Diagnostic Test: Spirometry
Spirometry will be performed in accordance with the current American Thoracic Society
recommendations for the performance and interpretation of tests.
Other: Psychosocial questionnaire: Additional Health Questionnaire
Single question over the last 3 months/90 days about cannabis use for GI problems and
appetite. The clinical sites will not see the responses to this question. It will be
completed by the participant online either during the study visit or at home.
Other: CF Management Questionnaire
Assessment of prior 12-month management of cystic fibrosis, including treatments,
medication intake and hospitalizations. This questionnaire will only be completed at 24-
and 36- month visits.
Other: Food Frequency Questionnaire
Assessment of prior 12-month nutritional intake being completed at Baseline (no later
than 6-month visit) and 12-month visit.
Cohort 2
FEV1 ≥70% predicted during the 12 months prior to enrollment (>50% of measurements,
eliminating periods of exacerbation).
Diagnostic Test: BMI and lean mass index from DXA
Estimate and compare correlation between lean mass index from DXA and BMI
Diagnostic Test: Anthropometric Measurements
Skinfold will be assessed with calipers. Circumference will be measured with a tape
measure.
Diagnostic Test: Hand-grip strength
A small, handheld dynamometer will be used to measure grip strength, a measure of
function, on each hand.
Diagnostic Test: Six-minute walk Test
This will be another functional assessment of fitness. Participants will be asked to walk
at their normal pace for 6 minutes.The total distance walked in that time will be
measured.
Diagnostic Test: Sit-to-Stand Test
This will be used as a functional assessment of fitness and lower extremity strength.
Participants will start seated on a chair and be asked to complete as many sit-to-stand
repetitions without using their arms for one minute.
Diagnostic Test: Short physical performance battery (SPPB)
This is an assessment of frailty. The test is completed in approximately 8 minutes. The
test consists of 3 assessments: 1) Balance tests where the participant stands and tries
to balance with their feet in various positions for 10 seconds each without assistance
(side-by-side, heel-to-side, and heel-to-toe); 2) Two 4-meter gait speed tests; and 3)
Chair-stand tests (single chair stand, 5 chair stands).
Diagnostic Test: BIA Sub-study
A minimum of 50 individuals will be enrolled. Body composition will be assessed at each
study visit using study bioelectrical impendence analysis (BIA).
Diagnostic Test: Accelerometry to assess physical activity
Participants will be provided with a wrist-worn accelerometer/heart rate monitor at the
baseline study visit and asked to wear it continuously for at least 3-10 days (two
weekdays, one weekend day). Approximately every 3 months, the participant will be asked
to again wear the accelerometer. Participants will be able to keep their accelerometers.
Other: Gastrointestinal (GI) and nutrition questionnaires:
Subjects will complete surveys regarding gastrointestinal (GI) symptoms, including the
Patient Assessment of Constipation (PAC-SYM) Score, Patient Assessment of
Gastrointestinal Symptoms (PACGI-SYM) Score, the Bristol Stool Chart, and the scored
Patient-Generated Subjective Global Assessment (PG-SGA).
Other: Psychosocial questionnaire: PHQ-8
This is an 8-item scale that measures depressive symptoms over the past two weeks.
Other: Psychosocial questionnaire: GAD-7
This is a 7-items scale that measures anxiety symptoms over the past two weeks, from not
at all to nearly every day.
Other: Psychosocial questionnaire: The Treatment Self-Regulation Questionnaire (TSRQ)
This is a 15-item scale that assesses the degree to which participants' motivation is
autonomous or self-regulated.
Other: Psychosocial questionnaire: CF Fatalism Scale
The CF Fatalism Scale measures the belief in a lack of personal power or control over
one's future and has 13 items.
Other: Psychosocial questionnaire: Body Esteem Scale for Adolescents and Adults (BESAA)
The Body Esteem Scale for Adolescents and Adults (BESAA) is 23-item measurement of
self-evaluations of one's body or appearance.
Other: 12-month Questionnaire
A short questionnaire designed to explore participants' perspectives of the acceptability
and feasibility of nutritional assessments used in STRONG-CF will be given to all study
participants at the end of the study.
Other: Oral glucose tolerance testing (OGTT)
For subjects without previously diagnosed CFRD, an OGTT will be performed at baseline and
12-months with samples analyzed at the central lab.
Device: Continuous glucose monitoring (CGM)
Subjects will wear a Dexcom G6Pro sensor in blinded mode for three 10-day periods to
collect comprehensive glucose data.
Diagnostic Test: Chest CT scans (When available within the past 6 months in medical records)
Standard of Care chest CT images will be drawn from the medical record, as available,
from enrolled participants. FEV1 measurements prior to chest CT scans will be recorded to
account for possible illness occurring at the time of scanning. Quantitative assessment
of the pectoralis muscle area will be performed on the first single axial image above the
aortic arch. Any additional standard of care chest CT's that are performed while the
participant is enrolled in the study will also be collected and have a quantitative
assessment of the pectoralis muscle performed.
Diagnostic Test: Hologic Dual X-Ray Absorptiometry (DXA)
DXA measurements for whole body, total hip and lumbar spine will be acquired using the
Hologic DXA and standard positioning as noted in the DXA Manual of Operations. DXA will
be used to estimate total and regional body composition, which will include body fat and
lean body mass. This will be used as the gold standard from which to validate BIA and
MAMC.
Diagnostic Test: Ultrasound Sub-study of assessment of appendage muscles using ultrasound
A minimum of 50 individuals will be enrolled. At each study visit, participants will
undergo ultrasound muscle measurements (cross-sectional area and muscle thickness) of the
biceps and quadriceps on each (left and right) side of the body (4 total areas). These
measurements will be obtained in triplicate for each patient.
Diagnostic Test: Psychosocial questionnaire: Hunger Vital Sign questionnaire
Screening tool for identifying households at risk of food insecurity and poor health
outcomes linked to food insecurity with 3-items over the last 12 months.
Other: Respiratory symptom questionnaire: CRISS
Chronic Respiratory Infection Symptom Score (CRISS) is an 8-item respiratory symptom
questionnaire covering the last 24-hours.
Diagnostic Test: Spirometry
Spirometry will be performed in accordance with the current American Thoracic Society
recommendations for the performance and interpretation of tests.
Other: Psychosocial questionnaire: Additional Health Questionnaire
Single question over the last 3 months/90 days about cannabis use for GI problems and
appetite. The clinical sites will not see the responses to this question. It will be
completed by the participant online either during the study visit or at home.
Other: CF Management Questionnaire
Assessment of prior 12-month management of cystic fibrosis, including treatments,
medication intake and hospitalizations. This questionnaire will only be completed at 24-
and 36- month visits.
Other: Food Frequency Questionnaire
Assessment of prior 12-month nutritional intake being completed at Baseline (no later
than 6-month visit) and 12-month visit.
Recruiting Locations
University of Arizona
Tucson 5318313,
Arizona 5551752
85724
Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health).
The listing of studies provided is not certain to be all studies for which you might be eligible.
Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.
